Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, the largest gene in the human genome, located on the X chromosome. About 65% of cases involve large deletions where entire sections of the gene are missing. The remaining cases stem from duplications (roughly 10%), small point mutations (about 25%), or rare complex rearrangements (less than 1%). What these mutations share is that they prevent muscle cells from producing functional dystrophin protein.
The Dystrophin Gene and Why Size Matters
The dystrophin gene sits on the short arm of the X chromosome at a position called Xp21.2. It is enormous, spanning about 2.4 million base pairs of DNA, which makes it an unusually large target for genetic errors. The protein it produces is equally long because its job demands it: dystrophin acts as a physical bridge inside muscle cells, connecting the internal scaffolding of the cell to the outer membrane. One end hooks into the cell’s interior framework while the other end latches onto proteins embedded in the membrane.
During a contraction, dystrophin transfers mechanical force from inside the muscle cell outward to the membrane. It also serves as an anchor point, holding other important molecules in position near the cell surface. Without it, the entire structural chain falls apart.
Large Deletions Are the Most Common Cause
Roughly two out of three DMD cases result from large deletions, where one or more entire exons (the protein-coding segments of the gene) are removed. These aren’t subtle spelling errors in the genetic code. They’re wholesale removal of chunks of the gene, sometimes spanning dozens of exons at once. Duplications, where exons are repeated, account for about 10% of cases. The remaining quarter comes from smaller mutations: nonsense mutations that insert a premature stop signal, small insertions or deletions of just a few DNA letters, or errors that disrupt how the gene’s instructions are read and spliced together.
The Reading Frame Rule
The critical factor that separates severe DMD from the milder Becker muscular dystrophy (BMD) isn’t the size of the mutation. It’s whether the mutation disrupts the gene’s “reading frame.” DNA is read in groups of three letters at a time, and each group codes for one building block of the protein. If a deletion removes whole groups of three without shifting the remaining sequence out of alignment, the cell can still produce a shorter but partially functional dystrophin protein. That’s Becker muscular dystrophy.
In DMD, deletions shift the reading frame so that every instruction downstream of the break becomes garbled. The cell either produces a completely nonfunctional protein or, more commonly, no dystrophin at all. This is why a person missing 20 exons might have milder Becker MD while someone missing just one or two exons has severe Duchenne: what matters is whether the remaining code still makes sense when read in threes.
X-Linked Inheritance and Spontaneous Mutations
Because the dystrophin gene sits on the X chromosome, DMD follows an X-linked recessive pattern. Boys have one X and one Y chromosome, so a single mutated copy of the gene is enough to cause disease. Girls have two X chromosomes, so a working copy on the second X typically compensates. A carrier mother has a 50% chance of passing the mutated gene to each child. Sons who inherit it will have DMD; daughters who inherit it will generally be carriers.
About one-third of all DMD cases arise from new, spontaneous mutations with no prior family history. In these sporadic cases, the mutation may have occurred fresh in the child, or the mother may carry the mutation in some of her egg cells without it appearing in a standard blood test. When researchers break down the probabilities for a mother of a sporadic case, about 68% of the time she turns out to be a carrier, about 19% of the time the mutation exists only in a fraction of her egg cells, and about 13% of the time the mutation is truly new in the child.
How Missing Dystrophin Destroys Muscle
Without dystrophin bridging the inside of the cell to the membrane, the membrane becomes fragile and leaky. Every time the muscle contracts, especially during lengthening movements like walking downstairs, the unprotected membrane tears. These micro-injuries, sometimes called delta lesions, allow calcium to flood into the cell and muscle enzymes like creatine kinase to leak out into the bloodstream. Elevated creatine kinase in a blood test is one of the earliest red flags for DMD, often detected before obvious muscle weakness appears.
The calcium overload is toxic. It triggers destructive processes inside the cell, increases oxidative stress, and eventually kills the muscle fiber. Damaged fibers release molecular distress signals that attract immune cells, sparking inflammation. Early on, the body can clear damaged fibers and regenerate new ones. But the damage never stops, so inflammation becomes chronic rather than healing. Over time, the muscle’s ability to regenerate wears out, and muscle tissue is gradually replaced by scar tissue and fat. This is why boys with DMD typically lose the ability to walk by their early teens, with the heart and breathing muscles affected later.
How the Mutation Type Is Identified
Genetic testing for DMD typically follows a two-step approach. Since whole-exon deletions and duplications account for about 78% of all disease-causing mutations, the first test looks specifically for these large changes. The most widely used method for this initial screen is a technique called MLPA, which checks each exon of the dystrophin gene for missing or extra copies.
If no deletion or duplication is found but DMD is still suspected, the next step is sequencing the entire coding region of the gene to look for smaller mutations: single-letter changes, small insertions, or splicing errors. Newer sequencing technologies can now detect both large and small mutations in a single test, though the stepwise approach remains common in many labs.
Why Mutation Type Matters for Treatment
Knowing the exact mutation isn’t just important for diagnosis. It determines which treatments a patient may be eligible for. One of the most promising therapeutic strategies, called exon skipping, uses small molecules to trick the cell’s machinery into skipping over the problematic exon during protein production. This restores the reading frame so the cell can produce a shorter but partially functional dystrophin, essentially converting severe DMD into something closer to milder Becker MD.
Four FDA-approved exon-skipping therapies currently target exons 45, 51, and 53, which correspond to the most common deletion hotspots. Exon 51 skipping is applicable to about 17% of patients with large deletions. Exon 45 skipping covers roughly 15%, and exon 53 skipping about 14%. Combined, these three targets address a meaningful fraction of patients, but because DMD mutations are so varied, no single therapy works for everyone. Additional exon-skipping targets, including exon 44 (applicable to about 11% of deletions), are in development to expand coverage.